LncRNA RUSC1-AS1 Promotes Osteosarcoma Progression Through Regulating the MiR-340-5p and PI3K/AKT Pathway

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 May 28

PMID 34048366

Citations 13

Authors

Chang-Jun Tong

Qing-Chun Deng

Di-Jun Ou

Xia Long

He Liu

Kang Huang

Affiliations

Soon will be listed here.

Abstract

Dysregulation of long noncoding RNA (lncRNA) is frequently involved in the progression and development of osteosarcoma. LncRNA RUSC1-AS1 is reported to be upregulated and acts as an oncogene in hepatocellular carcinoma, cervical cancer and breast cancer. However, its role in osteosarcoma has not been studied yet. In the present study, we investigated the role of RUSC1-AS1 in osteosarcoma both and . The results showed that the expression of RUSC1-AS1 was significantly upregulated in osteosarcoma cell line U2OS and HOS compared to that in human osteoblast cell line hFOB1.19. Similar results were found in human samples. Silencing RUSC1-AS1 by siRNA significantly inhibited U2OS and HOS cell proliferation and invasion, measured by CCK-8 and transwell assay. Besides, knockdown of RUSC1-AS1 increased cell apoptosis in osteosarcoma cell lines. In addition, RUSC1-AS1 promoted the epithelial-mesenchymal transition (EMT) process of osteosarcoma cells. experiments confirmed that RUSC1-AS1 knockdown had an inhibitory effect on osteosarcoma tumor growth. Mechanically, we showed that RUSC1-AS1 directly binds to and inhibits miR-340-5p and activates the PI3K/AKT signaling pathway. In conclusion, our study demonstrated that RUSC1-AS1 promoted osteosarcoma development both and through sponging to miR-340-5p and activating the PI3K/AKT signaling pathway. Therefore, RUSC1-AS1 becomes a potential therapeutic target for osteosarcoma.

Citing Articles

Role of long noncoding RNAs in the regulation of epithelial‑mesenchymal transition in osteosarcoma (Review).

Li Z, Tian Y Oncol Rep. 2025; 53(3).

PMID: 39930817 PMC: 11783035. DOI: 10.3892/or.2025.8868.

Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma.

Shao W, Feng Y, Huang J, Li T, Gao S, Yang Y Open Life Sci. 2024; 19(1):20220936.

PMID: 39119480 PMC: 11306965. DOI: 10.1515/biol-2022-0936.

The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma.

Wen J, Wan L, Chen W, Dong X J Orthop Surg Res. 2024; 19(1):356.

PMID: 38879525 PMC: 11179372. DOI: 10.1186/s13018-024-04781-1.

Anti-cancer targets and molecular mechanisms of formononetin in treating osteosarcoma based on network pharmacology.

Chen L, Zhou Y, Weng Z, Liu S, Li T, Wang Y Aging (Albany NY). 2023; 15(20):11489-11507.

PMID: 37870753 PMC: 10637808. DOI: 10.18632/aging.205139.

A new marker constructed from immune-related lncRNA pairs can be used to predict clinical treatment effects and prognosis: in-depth exploration of underlying mechanisms in HNSCC.

Fan X, Huang Y, Zhong Y, Yan Y, Li J, Fan Y World J Surg Oncol. 2023; 21(1):250.

PMID: 37592311 PMC: 10433616. DOI: 10.1186/s12957-023-03066-x.

References

Arndt C, Crist W . Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999; 341(5):342-52. DOI: 10.1056/NEJM199907293410507. View

Zhao P, Ma W, Hu Z, Zhang Y, Zhang S, Wang Y . Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4. J Endocrinol Invest. 2018; 41(10):1165-1172. DOI: 10.1007/s40618-018-0848-6. View

Yao J, Li J, Geng P, Li Y, Chen H, Zhu Y . Knockdown of a HIF-2α promoter upstream long noncoding RNA impairs colorectal cancer stem cell properties in vitro through HIF-2α downregulation. Onco Targets Ther. 2015; 8:3467-74. PMC: 4664519. DOI: 10.2147/OTT.S81393. View

Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y . lncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell. 2014; 159(5):1110-1125. PMC: 4266991. DOI: 10.1016/j.cell.2014.10.013. View

Shi X, Sun M, Liu H, Yao Y, Song Y . Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013; 339(2):159-66. DOI: 10.1016/j.canlet.2013.06.013. View

Chen L . Linking Long Noncoding RNA Localization and Function. Trends Biochem Sci. 2016; 41(9):761-772. DOI: 10.1016/j.tibs.2016.07.003. View

Xia Y, He Z, Liu B, Wang P, Chen Y . Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway. Mol Med Rep. 2015; 12(3):4530-4537. DOI: 10.3892/mmr.2015.3897. View

Zhu K, Ma X, Zhang C . LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR-3182/MMP2 Axis. Mol Ther. 2017; 25(10):2383-2393. PMC: 5628795. DOI: 10.1016/j.ymthe.2017.06.027. View

Song L, Duan P, Gan Y, Li P, Zhao C, Xu J . MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma. Braz J Med Biol Res. 2017; 50(5):e6359. PMC: 5441287. DOI: 10.1590/1414-431X20176359. View

10.

Xia W, Lin Q, Shen D, Liu Z, Su J, Mao W . Clinical implication of long noncoding RNA 91H expression profile in osteosarcoma patients. Onco Targets Ther. 2016; 9:4645-52. PMC: 4968861. DOI: 10.2147/OTT.S103376. View

11.

Martin-Broto J, Redondo A, Valverde C, Vaz M, Mora J, Garcia Del Muro X . Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann Oncol. 2017; 28(12):2994-2999. DOI: 10.1093/annonc/mdx536. View

12.

Yu X, Hu L, Li S, Shen J, Wang D, Xu R . Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p. Cell Death Dis. 2019; 10(4):280. PMC: 6433912. DOI: 10.1038/s41419-019-1509-1. View

13.

Godinho M, Wulfkuhle J, Look M, Sieuwerts A, Sleijfer S, Foekens J . BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer. 2012; 107(6):947-55. PMC: 3464772. DOI: 10.1038/bjc.2012.351. View

14.

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

15.

Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F . High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant. 2001; 27(9):933-7. DOI: 10.1038/sj.bmt.1703023. View

16.

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

17.

Niinaka Y, Harada K, Fujimuro M, Oda M, Haga A, Hosoki M . Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res. 2010; 70(22):9483-93. PMC: 2982894. DOI: 10.1158/0008-5472.CAN-09-3880. View

18.

Godinho M, Meijer D, Setyono-Han B, Dorssers L, van Agthoven T . Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol. 2011; 226(7):1741-9. DOI: 10.1002/jcp.22503. View

19.

Ochs J, Freeman A, Douglass Jr H, Higby D, Mindell E, Sinks L . cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep. 1978; 62(2):239-45. View

20.

Gao T, He B, Pan Y, Xu Y, Li R, Deng Q . Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression. Mol Carcinog. 2014; 54(5):359-67. DOI: 10.1002/mc.22106. View